Clinical toxicity of synthetic cannabinoid receptor agonist use

被引：0
|
作者：
Manini, Alex F. [1 ]
Hoffman, Robert S. [2 ]
Stimmel, Barry [3 ]
Vlahov, David [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Div Med Toxicol, New York, NY 10029 USA
[2] NYU, Sch Med, Div Med Toxicol, New York, NY USA
[3] Icahn Sch Med Mt Sinai, Div Cardiol, New York, NY 10029 USA
[4] UCSF Sch Nursing, Off Dean, San Francisco, CA USA
来源：
CLINICAL TOXICOLOGY | 2015年 / 53卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
269
引用
收藏
页码：356 / 357
页数：2
相关论文
共 50 条
  • [21] Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2
    Nallapaneni, Anuradha
    Liu, Jing
    Karanth, Subramanya
    Pope, Carey
    [J]. TOXICOLOGY, 2006, 227 (1-2) : 173 - 183
  • [22] In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018
    Gamage, Thomas F.
    Barrus, Daniel G.
    Kevin, Richard C.
    Finlay, David B.
    Lefever, Timothy W.
    Patel, Purvi R.
    Grabenauer, Megan A.
    Glass, Michelle
    McGregor, Iain S.
    Wiley, Jenny L.
    Thomas, Brian F.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2020, 193
  • [23] Clinical features following analytically confirmed use of 5F-ADB, a synthetic cannabinoid receptor agonist. A report from the UK IONA study
    Elamin, Muhammad E. M. O.
    Dunn, Michael
    Dargan, Paul I.
    Wood, David M.
    Tucker, Simon
    Hill, Simon L.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2017, 55 (05) : 443 - 444
  • [24] Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service
    Waugh, Jennifer
    Najafi, Javad
    Hawkins, Leonard
    Hill, Simon L.
    Eddleston, Michael
    Vale, J. Allister
    Thompson, John P.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (06) : 512 - 518
  • [25] Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety
    Gardin, Anne
    Kucher, Klaus
    Kiese, Beate
    Appel-Dingemanse, Silke
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (04) : 827 - 833
  • [26] Clinical characteristics of ED patients reporting synthetic cannabinoid use
    Huecker, Martin
    Warf, Corey
    Shoff, Hugh W.
    Ems, Thomas
    Webb, Ashley N.
    Persaud, Annuradha
    Furmanek, Stephen
    Buckner, Kimberly
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2019, 37 (07): : 1362 - 1363
  • [27] Cannabinoid Agonist Reduces Cannabis Use
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [28] Synthetic cannabinoid receptor agonist (SCRA) detection from pooled urine samples in central London
    Archer, John R. H.
    Hudson, Simon
    Abouchedid, Rachelle
    Ho, James
    Wood, David M.
    Dargan, Paul I.
    [J]. CLINICAL TOXICOLOGY, 2017, 55 (05) : 451 - 451
  • [29] Severe Toxicity Following Synthetic Cannabinoid Ingestion
    Lapoint, J.
    James, L. P.
    Moran, C. L.
    Nelson, L. S.
    Hoffman, R. S.
    Moran, J. H.
    [J]. CLINICAL TOXICOLOGY, 2011, 49 (08) : 760 - 764
  • [30] Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor
    Yano, Hideaki
    Chitsazi, Rezvan
    Lucaj, Christopher
    Tran, Phuong
    Hoffman, Alexander F.
    Baumann, Michael H.
    Lupica, Carl R.
    Shi, Lei
    [J]. ACS CHEMICAL NEUROSCIENCE, 2023, 14 (21): : 3928 - 3940
12345